Abstract:Introduction: Azole resistance has been increasingly reported and become an issue for clinical managements of invasive mycoses. New strategy with combination therapy arises as a valuable and promising alternative option. The aim of the present study is to investigate the in vitro combinational effect of proton pump inhibitors (PPIs) and azoles against pathogenic fungi. Methods: In vitro interactions of PPIs including omeprazole (OME), lansoprazole (LAN), pantoprazole (PAN), and rabeprazole (RAB), and commonly used azoles including itraconazole (ITC), posaconazole (POS), voriconazole (VRC) and FLC, were investigated via broth microdilution chequerboard procedure adapted from the CLSI M27-A3 and M38-A2. A total of 67 clinically isolated strains, namely 27 strains of Aspergillus spp., 16 strains of Candida spp., and 24 strains of dematiaceous fungi, were studied. C. parapsilosis (ATCC 22019) and A. flavus (ATCC 204304) was included to ensure quality control. Results: PPIs individually did not exert any significant antifungal activity. The combination of OME with ITC, POS, or VRC showed synergism against 77.6%, 86.6%, and 4% strains of tested pathogenic fungi, respectively, while synergism of OME/FLC was observed in 50% strains of Candida spp. Synergism between PAN and ITC, POS, or VRC was observed against 47.8%, 77.6% and 1.5% strains of tested fungi, respectively, while synergism of PNA/FLC was observed in 50% strains of Candida spp. Synergism of LAN with ITC, POS, or VRC was observed against 86.6%, 86.6%, and 3% of tested strains, respectively, while synergism of LAN/FLC was observed in 31.3% strains of Candida spp. Synergy of the combination of RAB with ITC, POS, or VRC was observed against 25.4%, 64.2%, and 4.5% of tested strains, respectively., synergism of RAB/FLC was observed in 12.5% of Candida spp.. Among PPIs, synergism was least observed between RAB and triazoles, while among triazoles, synergism was least observed between VRC and PPIs. Among species, synergy was much more frequently observed in Aspergillus spp. and dematiaceous fungi as compared to Candida spp. Antagonism between PPIs with ITC or VRC was occasionally observed in Aspergillus spp. and dematiaceous fungi. It is notable that PPIs combined with azoles showed synergy against azole resistant A. fumigatus , and resulted in category change of susceptibility of ITC and POS against Candida spp. Discussion: The results suggested that PPIs combined with azoles has the potential to enhance the susceptibilities of azoles against multiple pathogenic fungi and could be a promising strategy to overcome azole resistance issues. However, further investigations are warranted to study the combinational efficacy in more isolates and more species, to investigate the underlying mechanism of interaction and to evaluate the potential for concomitant use of these agents in human.

In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans: Synergy of PAB and FLC against Candida albicans

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

Synergistic Effect Of Pseudolaric Acid B With Fluconazole Against Resistant Isolates And Biofilm Of Candida Tropicalis

Novel Potentially Antifungal Hybrids of 5-Flucytosine and Fluconazole: Design, Synthesis and Bioactive Evaluation.

Synergistic Antifungal Effect of Fluconazole Combined with Licofelone Against Resistant Candida Albicans

The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans

Pseudolaric Acid A: A Promising Antifungal Agent Against Prevalent Non- albicans Candida Species

A mechanism study on the synergistic effects of rifapentine and fluconazole against fluconazole-resistant Candida albicans in vitro

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

In vitro interactions of proton pump inhibitors and azoles against pathogenic fungi

The synergistic antifungal effect and potential mechanism of D-penicillamine combined with fluconazole against Candida albicans

Synergistic Effect of Berberine Hydrochloride and Fluconazole Against Candida albicans Resistant Isolates

Anti- Candida Activity of New Azole Derivatives Alone and in Combination with Fluconazole

Paeonol assists fluconazole and amphotericin B to inhibit virulence factors and pathogenicity of Candida albicans

Potent Antifungal Activity of Pure Compounds from Traditional Chinese Medicine Extracts Against Six Oral Candida Species and the Synergy with Fluconazole Against Azole-Resistant Candida Albicans

Synergistic effect of eravacycline combined with fluconazole against resistant Candida albicans in vitro and in vivo

Antifungal Activity and Potential Mechanism of 6,7, 4′-O-Triacetylscutellarein Combined With Fluconazole Against Drug-Resistant C. albicans

Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo

Novel aza-bicyclic 2-isoxazoline acylhydrazone hybrids and their synergistic potential with fluconazole against a drug-resistant Candida albicans strain

Fluconazole Inhibits Cellular Ergosterol Synthesis to Confer Synergism with Berberine Against Yeast Cells.

The Synergism of the Small Molecule ENOblock and Fluconazole Against Fluconazole-Resistant Candida Albicans